Expeditious Advancements in 3D Printing Technologies Propel Bioresorbable Polymers Market
The bioresorbable polymers market is witnessing a surge in growth propelled by the rapid evolution of 3D printing technologies. In the realm of medical devices, such as fixation plates, screws, sutures, and scaffolds for tissue engineering, bioresorbable polymers take center stage. Over the past decade, the adoption of 3D printing for clinical and research purposes in medicine has seen a substantial uptick, offering a paradigm shift in manufacturing possibilities. The technology's capability to craft intricate porous geometries, vital for scaffolds but unattainable through traditional production methods, underscores its transformative potential.
In the medical and dental industry, 3D printing technology emerges as a game-changer for creating and optimizing medical device designs. The advent of low-cost rapid prototyping has kindled increased interest and flexibility among medical device manufacturers in designing novel products, thereby expediting the introduction of new medical devices to the market. Notably, prosthetics and implants can be produced more affordably than through traditional technologies, as 3D printing not only reduces costs but also accelerates the production timeline.
Although the medical sector constitutes a fraction of the broader additive manufacturing market, it continually pioneers innovative applications for 3D printing technology. Patients are already benefiting from personalized 3D-printed implants and prostheses tailored to their unique anatomies. Cases of newborns with rare tracheal abnormalities have been successfully addressed through 3D printing, exemplifying its life-saving potential. The landscape of joint replacements and bone restoration therapies is undergoing transformation due to additive manufacturing techniques, enabling a degree of customization previously unattainable. Polylactic acid (PLA) stands out as the most frequently utilized bioresorbable polymer in biomedical applications within 3D printing, particularly in orthosis and prosthesis. The medical sector is witnessing groundbreaking innovations, ranging from 3D-printed human body implants to the development of cardiac tissues, all leveraging polymers for prototyping or implant production.
According to Statista, the global market for 3D printing products and services is poised for robust growth, projected to reach USD 37.2 billion by 2026, as depicted in the graph below. This foretells a promising trajectory for the rapid advancement of 3D printing technology, signifying lucrative opportunities for the continued expansion of the bioresorbable polymers market. As 3D printing becomes increasingly integral to the medical landscape, the symbiotic relationship between this technology and bioresorbable polymers is set to redefine the possibilities in healthcare applications, offering tailored solutions for patients and unlocking new dimensions of innovation.
Report Attribute/Metric | Details |
---|---|
Market Opportunities | Rapid growth in 3d printing technologies |
Market Dynamics | Increasing demand for bioresorbable polymers for drug delivery application Flourishing the healthcare industry |
Bioresorbable polymers Market Size was valued at USD 1,311.16 million in 2021. The Bioresorbable polymers industry is projected to grow from USD 1,399.16 million in 2022 to USD 3,672.96 million by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8% during the forecast period (2022 - 2030). Bioresorbable polymers are widely used in the healthcare sector, especially in the drug delivery system. The use of bioresorbable polymers in various applications such as orthopedic and dental is projected to boost the demand for bioresorbable polymers during the forecast period. The use of bioresorbable polymers is flourishing in the healthcare industry which is expected to drive the bioresorbable polymers market in the coming years.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Polymers have significantly contributed to the improvement of drug delivery technology by enabling the regulated release of therapeutic agents in consistent dosages over extended periods, cyclic dosing, and various releases of both hydrophilic and hydrophobic medicines. The area has expanded significantly from its early days of employing common materials. The rational design of polymers made to exert certain biological activities and customized for a specific cargo is currently the foundation for contemporary advancements in drug delivery. Bioresorbable polymers provide monitored release to the needed site, stability to imbalanced molecules (e.g., proteins), and has ability to alter surfaces with ligands for secrecy and targeted drug delivery purposes in the human body.
In polymer therapies and nanomedicines, polymers have been used extensively. Solid, mostly spherical structures made from organic or synthetic polymers are known as polymeric nanoparticles. One of the most significant biological uses of polymeric nanoparticles is drug delivery. A variety of drug delivery systems, including tiny hydrophilic and hydrophobic medicines, vaccines, peptides, and biological macromolecules, have been tested to deliver polymeric nanoparticles. The biodegradable polymers that produce polymeric nanoparticles most successfully include various grades of poly(lactide-co-glycolide) and poly(lactide) copolymers. Hence extensive properties of bioresorbable polymers for novel drug delivery systems, nanomedicines, and others will drive the bioresorbable polymers market in the forecast period. Thus, increasing demand for drug delivery systems from the medical sector industry is a factor driving the growth of the Bioresorbable polymers market revenue.
In September 2023, Zeus, a leader in global advanced polymer solutions, announced that it had developed Absorv™ XSE oriented tubing. It is the latest addition to its portfolio of bioabsorbable products. Absorb XSE comes in different resins and expanded sizes, which make it highly customizable and an alternative to metallics implanted permanently within the human body. With this flexibility, medical device manufacturers can consider other applications of BRS beyond coronary artery disease treatment. Further developments can be made within the cardiovascular system, peripheral vascular system, and Ear Nose Throat (ENT), among others.
Evonik revealed the RESOMER Precise platform in June 2020, which represents a major advance in personalized functional polymeric excipients for custom drug products. With this technological novelty, pharmaceutical companies can develop parenteral drug delivery systems with unrivaled accuracy and precision in the control of their release profiles. In addition to improving drug product stability, the novel RESOMER platform also reduces regulatory risks associated with various complex parenteral drug products that are made using Evonik's advanced and unique process technology.
The Bioresorbable polymers market segmentation, based on type, includes agro-polymer and bio-polyesters. The bio-polyesters segment accounted for the largest market share in 2021, in the Bioresorbable polymers market revenue. Agro-polymers is further divided into proteins, and polysaccharides and bio-polyesters are further divided into polyglycolic acid, polylactic acid, polycaprolactone, polydioxanone, and others.The bio-polyesters are derived from renewable sources such as oil and fats. The various bio-polyesters commonly used are polyglycolic acid, polylactic acid, polycaprolactone, polydioxanone, and others.
The Bioresorbable polymers market segmentation, based on application, includes orthopedic, drug delivery, biodegradable devices, and others. The orthopedic segment accounted for the largest market share of 41.81% in 2021, with a market value of USD 549.46 million; it is expected to register a CAGR of 13.8% during the forecast period. Bioresorbable polymers such as polylactic acid (PLA) and polyglycolic acid (PGA) plays a prominent role in orthopedic as these polymers can be degraded by hydrolysis and enzymatic activity. They have strong physical and mechanical properties that are widely used in the production of medical devices for various orthopedic implant surgeries. The material used in an orthopedic implant will depend on the physical, mechanical, and degradation properties owing to the provide a better efficient product and beneficial for market growth.
February 2020: Evonik Industries AG has launched its world-first bioresorbable polymer in powder form, suitable for high-resolution printing of implantable medical devices. Craniomaxillofacial (CMF) plates, scaffolds for soft tissue repair, spinal fusion cages, and dental mesh are among the implantable products that can use powder-based polymers to improve patient healing and device performance across dental, orthopedic, and soft tissue application areas.
Figure 2: Bioresorbable polymers Market, by Application, 2021 & 2030 (USD Million)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By Region, the study segments the market into North America, Europe, Asia-Pacific and Rest of the World. Among these, North America dominated the market with a share of 44.03%, accounting for USD 578.60 million in 2021; it is expected to register the highest CAGR of 12.60% from 2022 to 2030. Europe was the second largest with a share of 25.92% in 2021, sized at USD 340.59 million; it is projected to exhibit a CAGR of 11.9%.The North American market is mainly driven by the availability of raw materials and increasing demand for bioresorbable polymers across the region for various applications in medical, pharmaceutical, and others. Due to economic changes and increased per capita income, the healthcare sector is expanding throughout North America, including the US and Canada.
Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: Bioresorbable polymers MARKET SHARE BY REGION 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Bioresorbable polymers market accounts for the second-largest market share Bioresorbable polymers market is largely supplied by European countries such as the UK and Germany. The growing demand for drug delivery systems in the region is likely to boost the demand for the Bioresorbable polymers market. Further, the Germany Bioresorbable polymers market held the largest market share, and the fastest-growing market in the European region
Major market players have large production bases and advanced manufacturing facilities at the domestic and international levels. This helps them supply the product to various end users across the globe within less time as compared to the small-scale manufacturers, providing a competitive edge in the market. The leading producers of merchant bioresorbable polymers are US, and Canada. According to MRFR analysis, the bioresorbable polymers market has a huge revenue base in European countries.
One of the primary business strategies adopted by manufacturers in the Bioresorbable polymers market to benefit clients and expand the Bioresorbable polymers market sector is to manufacture locally to reduce operating costs. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
Poly-Med Inc. is a leader in the design and production of bioresorbable products. The company operates in five business segments: Bioresorbable polymers, Biomedical textiles & Fiber, Electrospinning, Tissue scaffolds and devices, Polymer for Drug delivery, and 3D Printing Technology. Also, the company can provide customized solutions to meet the needs of innovative medical product manufacturers. Moreover, Poly-Med is the only vertically integrated company to deliver the highest quality solutions most efficiently.
Also, Merck KGaA is vibrant science and technology company with a diversified product portfolio. The company provides progressive treatment solutions that help improve access to health. Science sits inside technologies that drive human progress and opens new possibilities to transform lives. The advanced treatment solutions and innovative technology are life-changing, influencing to tackle of major illnesses and integral to creating a better tomorrow. The major business segments of the company are Life science, health care, and electronics.
Lygos Inc. launched its Soltellus line at NYSCC Suppliers' Day in May 2024; it was positioned as a high-performance, multi-functional, sustainable polymer for hair and skin care formulations. Skin care formulation under Soltellus acts as a co-surfactant with improved stability while providing a lathery, frothy foam that spreads easily and helps remove more dirt and oil impurities from deep pores. As an emulsifier, it improves user experience with a smoother application and luxurious after-feel, which keeps the formulation quality intact whilst ensuring the skin remains hydrated without any residue.
An FDA approval for the esprit BTK, an everolimus-eluting, PLLA peripheral stent treating chronic limb-threatening ischemia by Abbott was issued in April 2024 according to a report in 2024.
Dynamx™ Bioadaptor from Elixir is a drug-eluting stent with metallic and biodegradable aspects as per report of 2024. When this device is initially inserted into the vessel, its struts are locked so that maximum lumen flow can be achieved. When bioabsorbable components disappear, the structure "unlocks,” allowing the vessel to maintain pulsatility and adaptive flow volume.
In September 2020, DSM announced a partnership with PBC Biomed, an Ireland-based medical device design and development company. Their initial work together will be in developing regenerative bone adhesives for safe and cost-effective surgical procedures. This definitely qualifies as a key development in the industry.
Evonik Industries AG closed its acquisition of the LACTEL Absorbable Polymers product line from DURECT Corporation in December 2020. It is seen as a step forward in Evonik's life-science division Nutrition & Care's growth agenda.
In September 2020, Corbion and Total announced building a new PLA bioplastics plant in Europe through their Total Corbion PLA joint venture. This plant will be the first world-scale facility producing PLA located in Europe, with a capacity of about 100 kt per year. The French location is planned to start running in 2024. Additional investment into making more PLA will quicken lactic acid production expansion plans.
Bioresorbable polymers Type Outlook
Bioresorbable polymers Application Outlook
Bioresorbable polymers Regional Outlook
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)